Iron chelators: all 144 studies that test it

Page 1 of 2. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in SchizophreniaRecruitingNCT07759895Phase 2
• Effect of Chromium Weight Reduction on Adult Asthma ControlNot yet recruitingNCT07703358Not applicable
• Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingNCT07023666Phase 2
• Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell TransplantationRecruitingNCT06784336Phase 2
• Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction PatientsRecruitingNCT05604131Phase 2
• Thinking Zinc: a Study of Zinc Supplements on the Navajo NationRecruitingNCT03908736Phase 2
• Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young ChildrenCompletedNCT03591575Phase 4Results posted
• Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional HemosiderosisCompletedNCT03372083Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)TerminatedNCT03203850Phase 2Results posted
• Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible TabletCompletedNCT02993224Phase 2Results posted
• Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic SyndromeTerminatedNCT02943668Phase 2Results posted
• Study of Parkinson's Early Stage With DeferiproneCompletedNCT02728843Phase 2Results posted
• Extended Evaluation of Deferasirox Film-coated Tablet (FCT) FormulationCompletedNCT02720536Phase 3Results posted
• A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.TerminatedNCT02663752Phase 2Results posted
• Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy VolunteersCompletedNCT02465489Phase 1Results posted
• Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02443545Phase 4Results posted
• Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy VolunteersCompletedNCT02442310Phase 1Results posted
• Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron OverloadCompletedNCT02435212Phase 2Results posted
• Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65TerminatedNCT02341495Phase 2Results posted
• Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy VolunteersCompletedNCT02189941Phase 1Results posted
• Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated NeurodegenerationCompletedNCT02174848Phase 3Results posted
• Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.TerminatedNCT02159040Phase 2Results posted
• Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02041299Phase 4Results posted
• A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy VolunteersCompletedNCT01989455Phase 1Results posted
• Evaluation of Whether Deferiprone Affects QT Interval in Healthy SubjectsCompletedNCT01860703Phase 4Results posted
• Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric PatientsCompletedNCT01825512Phase 3Results posted
• Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia PatientsTerminatedNCT01818726Phase 4Results posted
• An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal ImpairmentCompletedNCT01770652Phase 4Results posted
• An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy VolunteersCompletedNCT01767103Phase 4Results posted
• Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)CompletedNCT01741532Phase 3Results posted
• Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent ThalassemiaCompletedNCT01709838Phase 4Results posted
• Combination Deferasirox and Deferiprone for Severe Iron Overload in ThalassemiaCompletedNCT01709032Phase 1/2Results posted
• Post Hematopoietic Stem Cell TransplantationCompletedNCT01610297Phase 4Results posted
• A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedNCT01539837Phase 2Results posted
• Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron OverloadTerminatedNCT01459718Phase 2Results posted
• Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability StudyTerminatedNCT01326845Phase 4Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCompletedNCT01254227Phase 2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).CompletedNCT01090323Phase 2Results posted
• Exjade-Early-TrialTerminatedNCT01058369Phase 2Results posted
• Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension StudyCompletedNCT01033747Phase 2/3Results posted
• Clinical Importance of Treating Iron Overload in Sickle Cell DiseaseTerminatedNCT00981370Phase 3Results posted
• A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)CompletedNCT00961662Phase 2Results posted
• Naturlose (D-Tagatose) Efficacy Evaluation TrialCompletedNCT00955747Phase 3Results posted
• Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy StudyCompletedNCT00940602Phase 2Results posted
• Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron OverloadCompletedNCT00901199Phase 2Results posted
• Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension StudyCompletedNCT00873041Phase 2Results posted
• Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to FoodCompletedNCT00845871Phase 4Results posted
• Pilot Study for Patients With Poor Response to DeferasiroxCompletedNCT00749515Phase 4Results posted
• Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional HemosiderosisCompletedNCT00631163Phase 2Results posted
• Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell TransplantTerminatedNCT00602446Phase 2Results posted
• Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron OverloadCompletedNCT00600938Phase 2Results posted
• Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea TardaCompletedNCT00599326Phase 3Results posted
• Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric PatientsCompletedNCT00529152Phase 3Results posted
• Cardiac T2* in Beta-thalassemia Patients on Deferasirox TreatmentCompletedNCT00447694Phase 2Results posted
• The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) StudyCompletedNCT00419770Phase 2Results posted
• Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary HemochromatosisCompletedNCT00395629Phase 1/2Results posted
• A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.CompletedNCT00390858Phase 2Results posted
• Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia PatientsCompletedNCT00303329Phase 2Results posted
• Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadCompletedNCT00235391Phase 3Results posted
• Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)CompletedNCT00171301Phase 4Results posted
• An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron OverloadCompletedNCT00171210Phase 3Results posted
• Study for the Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00117507Phase 4Results posted
• Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease PatientsCompletedNCT00110617Phase 2Results posted
• Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00110266Phase 2Results posted
• Efficacy of Chromium Picolinate in Reducing Acanthosis Nigricans Severity in Adolescents With Insulin ResistanceCompletedNCT07371169Not applicable
• Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron OverloadCompletedNCT06468423Not applicable
• Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell DiseaseCompletedNCT05392101Phase 2
• Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc TherapyTerminatedNCT04542993Phase 2
• Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDSTerminatedNCT03920657Phase 2
• Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to ChelationCompletedNCT03637556Phase 2
• Oral Lactoferrin Versus Iron Supplementation During PregnancyCompletedNCT03542825Phase 4
• Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA AgentsCompletedNCT03387475Phase 2
• Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral SclerosisCompletedNCT03293069Phase 2/3
• Deferiprone to Delay Dementia (The 3D Study)CompletedNCT03234686Phase 2
• Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose AdministrationCompletedNCT02980458Phase 1
• Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based TherapyStatus unknownNCT02882477Phase 2/3
• Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesCompletedNCT02880033Not applicable
• A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive ImpairmentWithdrawnNCT02878538Early Phase 1
• Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia MajorStatus unknownNCT02761395Not applicable
• Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseCompletedNCT02655315Phase 2
• Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS PatientsCompletedNCT02477631Phase 2
• Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive SubjectsCompletedNCT02456558Phase 1
• The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy RegimensStatus unknownNCT02413021Phase 1
• Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)CompletedNCT02233504Early Phase 1
• Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia PatientsCompletedNCT02198508Not applicable
• Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected SubjectsCompletedNCT02191657Phase 1
• An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major PatientsStatus unknownNCT02173951Phase 2/3
• Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) PatientsCompletedNCT02164253Phase 2
• Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent ThalassemiaWithdrawnNCT02069886Phase 4
• Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02038816Phase 2
• Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)Status unknownNCT01996683Not applicable
• Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High DosesWithdrawnNCT01948817Phase 2
• Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeWithdrawnNCT01892644Phase 2
• An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years OldWithdrawnNCT01724138Phase 4
• A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDSStatus unknownNCT01718366Phase 1/2
• Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E PatientsCompletedNCT01597765Not applicable
• Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron OverloadStatus unknownNCT01511848Phase 2/3
• Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast AgentWithdrawnNCT01391520Phase 3

← Iron chelators overview